Brief: Novan - Entered Into A Master Services Agreement With Catalent To Develop Intranasal Formulation Of Berdazimer Sodium For Covid-19 Program
21/12/2020 16:51
Dec 21 (Reuters) - Novan Inc NOVN.O :
* NOVAN - ENTERED INTO A MASTER SERVICES AGREEMENT WITH
CATALENT
TO DEVELOP INTRANASAL FORMULATION OF BERDAZIMER SODIUM FOR
COVID-19 PROGRAM
* NOVAN INC - TARGETS INITIATING PRECLINICAL INVESTIGATIONAL
NEW
DRUG (IND) ENABLING STUDIES IN Q1 2021
Source text for Eikon: ID:nGNX7QXjHr
Further company coverage: NOVN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NVN Liquidation
See all newsBrief: Nvn Liquidation Says On April 30, Debtors Filed Notice Of Effective Date With Bankruptcy Court
Brief: Novan Received Notice From Nasdaq Notifying Co's Securities Will Be Delisted From Nasdaq
Brief: Novan Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
U.S. STOCKS ON THE MOVE-Lands' End, Energy sector
U.S. STOCKS ON THE MOVE-Biogen, NetApp, LyondellBasell